SEPN Stock Analysis: Septerna, Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.533m USD | 12M Return: 230.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.0M
Qual. Beats: 0
Rev. Trend: 98.4%
Warnings
Tailwinds
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule therapies targeting G protein-coupled receptors (GPCRs) - the largest family of cell surface receptors and a major class of drug targets - for endocrinology, immunology/inflammation, and metabolic diseases. Its lead programs include an oral PTH1R agonist for hypoparathyroidism, SEP-631 (an MRGPRX2 negative allosteric modulator) for chronic spontaneous urticaria and mast cell diseases, and an oral TSHR NAM for Graves disease and thyroid eye disease, with additional exploratory work in neurology, womens health, cardiovascular, and respiratory indications. The company maintains a global collaboration and license agreement with Novo Nordisk to develop oral small molecule therapies for metabolic-related diseases. Founded in 2019 and headquartered in South San Francisco, California, Septerna was formerly known as GPCR NewCo, Inc. before adopting its current name in June 2021. As a clinical-stage company with no approved products, its business model centers on advancing candidates through early-stage trials and monetizing its pipeline through partnerships.
- PTH1R oral agonist Phase 1 data expected mid-2025
- Novo Nordisk collaboration delivers milestone payments and R&D funding
- Cash runway supports pipeline through key 2025-2026 clinical readouts
| Net Income: -36.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 36.24 > 1.0 |
| NWC/Revenue: 401.2% < 20% (prev 34.0k%; Δ -33.6k% < -1%) |
| CFO/TA 0.19 > 3% & CFO 107.9m > Net Income -36.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.8m) vs 12m ago 1.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 14.40% > 50% (prev 0.23%; Δ 14.17% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.51 (Total Current Assets 368.1m - Total Current Liabilities 78.2m) / Total Assets 569.7m |
| B: -0.31 (Retained Earnings -175.9m / Total Assets 569.7m) |
| C: -0.11 (EBIT TTM -53.8m / Avg Total Assets 501.9m) |
| D: 1.98 (Book Value of Equity 378.5m / Total Liabilities 191.2m) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 0.15 (Receivables 14.3m/1.33m, Revenue 72.3m/977k) |
| GMI: 1.02 (GM 100.0% / 97.78%) |
| AQI: 2.12 (AQ_t 0.31 / AQ_t-1 0.15) |
| SGI: 73.96 (Revenue 72.3m / 977k) |
| TATA: -0.25 (NI -36.0m - CFO 107.9m) / TA 569.7m) |
| Beneish M = 49.24 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 35.83 with a total of 837,153 shares traded. Over the past week, the price has changed by +3.11%, over one month by +17.82%, over three months by +44.24% and over the past year by +230.23%.
Current recommended Stop Loss: 33.20 (which is 7.3% or 1.2 ATR below the current price).
Septerna, Common Stock has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SEPN.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45 | 25.6% |
P/E Forward = 107.5269
P/S = 21.2105
P/B = 4.1263
Revenue TTM = 72.3m USD
EBIT TTM = -53.8m USD
EBITDA TTM = -52.1m USD
Long Term Debt = 20.8m USD (estimated: total debt 23.1m - short term 2.31m)
Short Term Debt = 2.31m USD (from shortTermDebt, last quarter)
Debt = 23.1m USD (from shortLongTermDebtTotal, last quarter) (leases 23.1m already included)
Net Debt = -324.3m USD (calculated: Debt 23.1m - CCE 347.4m)
Enterprise Value = 1.21b USD (1.53b + Debt 23.1m - CCE 347.4m)
Interest Coverage Ratio = unknown (Ebit TTM -53.8m / Interest Expense TTM 0.0)
EV/FCF = 11.30x (Enterprise Value 1.21b / FCF TTM 106.9m)
FCF Yield = 8.85% (FCF TTM 106.9m / Enterprise Value 1.21b)
FCF Margin = 148.0% (FCF TTM 106.9m / Revenue TTM 72.3m)
Net Margin = -49.88% (Net Income TTM -36.0m / Revenue TTM 72.3m)
Gross Margin = unknown ((Revenue TTM 72.3m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = 2.12 (Enterprise Value 1.21b / Total Assets 569.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 23.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -42.5m (EBIT -53.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.71 (Total Current Assets 368.1m / Total Current Liabilities 78.2m)
Debt / Equity = 0.06 (Debt 23.1m / totalStockholderEquity, last quarter 378.5m)
Debt / EBITDA = 6.22 (negative EBITDA) (Net Debt -324.3m / EBITDA -52.1m)
Debt / FCF = -3.03 (Net Debt -324.3m / FCF TTM 106.9m)
Total Stockholder Equity = 381.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.18% (Net Income -36.0m / Total Assets 569.7m)
RoE = -9.44% (Net Income TTM -36.0m / Total Stockholder Equity 381.7m)
RoCE = -13.36% (EBIT -53.8m / Capital Employed (Equity 381.7m + L.T.Debt 20.8m))
RoIC = -8.66% (negative operating profit) (NOPAT -42.5m / Invested Capital 490.2m)
WACC = 11.85% (E(1.53b)/V(1.56b) * Re(12.03%) + D(23.1m)/V(1.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.61 | Cagr: 53.83%
[DCF] Terminal Value 64.21% ; FCFF base≈106.9m ; Y1≈107.4m ; Y5≈113.7m
[DCF] Fair Price = 31.80 (EV 1.11b - Net Debt -324.3m = Equity 1.43b / Shares 45.1m; r=11.85% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 1.64k% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.49 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.55 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.84 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=-32.6% | GrowthRev=+67.5%
EPS next Year (2027-12-31): EPS=-2.66 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=-44.6% | GrowthRev=-14.4%
[Analyst] Revisions Ratio: +18% (up=5, down=3)